Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase III, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma

BACKGROUND: Treatment options for soft tissue sarcoma (STS) patients aged ≥65 years (elderly) can be limited by concerns regarding the increased risk of toxicity associated with standard systemic therapies. Trabectedin has demonstrated improved disease control in a phase III trial (ET743-SAR-3007) o...

全面介紹

Na minha lista:
書目詳細資料
發表在:Ann Oncol
Main Authors: Jones, R L, Demetri, G D, Schuetze, S M, Milhem, M, Elias, A, Van Tine, B A, Hamm, J, McCarthy, S, Wang, G, Parekh, T, Knoblauch, R, Hensley, M L, Maki, R G, Patel, S, von Mehren, M
格式: Artigo
語言:Inglês
出版: Oxford University Press 2018
主題:
Original Articles
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC6454486/
https://ncbi.nlm.nih.gov/pubmed/30084934
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdy253
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍